Inherited coagulation disorders in the northwestern region of Iran

Ziaei, Jamal Eivazi; Dolatkhah, Roya; Dastgiri, Saeed; MohammadpourAsl, Asghar; Asvadi, Iraj; Mahmoudpour, Ali; Nikanfar, Alireza; Malgaii, H.; Gholchin, Mehri; Vaez, Jalil

doi:10.1111/j.1365-2516.2005.01118.x

Cited by 9 publications

(11 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, 30 studies were selected for the analysis (19)(20)(21). It was noteworthy that no data was available from Egypt although this country has the highest number of hemophilia patients (4141) in the eastern Meditarranean region (27). In addition, we could not find any relevant study on HCV prevalence in patients with bleeding disorder from Bahrain, Kuwait, Jordan, Lebanon, Libya, Oman, Qatar, Emirates, Yemen, Sudan, Djibouti, Syria, Morocco, Somali, and Afghanistan.…”

Section: Search Results and Study Selectionmentioning

confidence: 39%

Lack of Knowledge About Hepatitis C Infection Rates Among Patients With Inherited Coagulation Disorders in Countries Under the Eastern Mediterranean Region Office of WHO (EMRO): A Meta-Analysis

Alavian

Aalaei‐Andabili²

2012

Hepat Mon

View full text Add to dashboard Cite

Context: Hepatitis C virus (HCV) infection is a public health problem. HCV alone is responsible for 90% cases of acute hepatitis among multiply transfused patients who are at risk of cirrhosis and hepatocellular carcinoma (HCC). Objectives: To provide a clear picture of available data, we performed a systematic review of the epidemiological characteristics of HCV infection among patients with inherited coagulation disorders in the countries under the Eastern Mediterranean Region Office (EMRO). Evidence Acquisition: Meta-analysis was carried out on the basis of results of electronic and manual search. This analysis included studies in English, French, and Persian that met with the following criteria: (1) appropriate study design: cross-sectional, case-control, and cohort; (2) studies reporting HCV prevalence according to enzyme immune assay; (3) studies in which the sample population was enrolled from EMRO countries. According to the results of the heterogeneity tests, we used fixed-effect/random-effect model for our meta-analysis, with the "Metan" command. Results:We included 30 studies, most of which were from Iran. The mean age of the subjects ranged from 13 to 27.1 years. The majority of the patients were male (range, 81% to 100%). The pooled estimate of HCV infection among patients with inherited coagulation disorders was 48.07% (95% confidence interval [CI], range: 27.39-55.68) in Iran, 36.03% (95% CI, range: 4.466-67.598) in Pakistan, and 48.27% (95% CI,) in all the EMRO countries taken together. Conclusions: In Iran and other EMRO countries, the HCV infection rate among patients with inherited coagulation disorders is high. Our study shows that there is a lack of knowledge about infections in such patients in most of the EMRO countries. It is the responsibility of health-policy makers to address this knowledge gap and provide safe and adequate treatment for patients in high-risk groups.

show abstract

Section: Search Results and Study Selectionmentioning

confidence: 39%

Lack of Knowledge About Hepatitis C Infection Rates Among Patients With Inherited Coagulation Disorders in Countries Under the Eastern Mediterranean Region Office of WHO (EMRO): A Meta-Analysis

Alavian

Aalaei‐Andabili²

2012

Hepat Mon

View full text Add to dashboard Cite

show abstract

“…Slovenia, Hungary and the Slovak Republic are intriguing examples that definitely merit further research. Consanguineous marriages are common in Iran and, therefore, coagulation disorders are observed more frequently than in many other countries [50,51]. This large patient population is accompanied by one of the highest FVIII IUs per PWHA for its economic classification (Table 3), suggesting that the identification of large patient population and advocacy through the Iran Hemophilia Center has influenced the consumption of FVIII to levels higher than expected based on economic status [52].…”

Section: Discussionmentioning

confidence: 99%

A study of reported factor VIII use around the world

Stonebraker

Brooker

Amand³

et al. 2009

Haemophilia

View full text Add to dashboard Cite

The effect of replacement therapy has significantly improved the morbidity and mortality of people with haemophilia A in high income countries, a recent socio-economic development as the availability of safe concentrates has been matched by a willingness for their provision through reimbursement. In the developing world, however, this state has not been achieved, primarily because of the low visibility of haemophilia coupled with its expense, leading to inadequate treatment with its sequelae of severe pain, joint deformities, arthropathy, disabilities, and even death in childhood or early adult life. The objective of this paper was to study the reported factor VIII (FVIII) use on a country-by-country basis. Data on the reported FVIII use for 104 countries were obtained from the Marketing Research Bureau, Inc. and the World Federation of Hemophilia. The results show that FVIII use varies considerably among countries, even among the wealthiest of countries. The use of FVIII concentrate increases as economic capacity increases; in addition, consumption of FVIII has been increasing at a greater rate in high income countries. Given these trends, there probably will be a global increase in FVIII concentrates usage. Such information is critical for national healthcare agencies to determine realistic budget priorities in planning for an increased allocation of resources required to improve the treatment of patients with haemophilia A. This information is also important for pharmaceutical manufacturers to adequately plan for increased production of FVIII concentrates.

show abstract

“…All the studies were carefully evaluated to avoid including duplicates or low-quality papers. Two letters to editors [27][28], and 1 review article were excluded [29]. One study was excluded because of low sample size.…”

Section: Resultsmentioning

confidence: 99%

“…Finally, 30 studies were selected for the analysis [19][20][21][36]-[62]. It was noteworthy that no data was available from Egypt although this country has the highest number of hemophilia patients (4141) in the eastern Meditarranean region [27]. In addition, we could not find any relevant study on HCV prevalence in patients with bleeding disorder from Bahrain, Kuwait, Jordan, Lebanon, Libya, Oman, Qatar, Emirates, Yemen, Sudan, Djibouti, Syria, Morocco, Somali, and Afghanistan.…”

Section: Resultsmentioning

confidence: 99%

Lack of Knowledge About Hepatitis C Infection Rates Among Patients With Inherited Coagulation Disorders in Countries Under the Eastern Mediterranean Region Office of WHO (EMRO): A Meta-Analysis

Alavian

Aalaei‐Andabili²

2012

Hepat Mon

View full text Add to dashboard Cite

ContextHepatitis C virus (HCV) infection is a public health problem. HCV alone is responsible for 90% cases of acute hepatitis among multiply transfused patients who are at risk of cirrhosis and hepatocellular carcinoma (HCC).ObjectivesTo provide a clear picture of available data, we performed a systematic review of the epidemiological characteristics of HCV infection among patients with inherited coagulation disorders in the countries under the Eastern Mediterranean Region Office (EMRO).Evidence AcquisitionMeta-analysis was carried out on the basis of results of electronic and manual search. This analysis included studies in English, French, and Persian that met with the following criteria: (1) appropriate study design: cross-sectional, case-control, and cohort; (2) studies reporting HCV prevalence according to enzyme immune assay; (3) studies in which the sample population was enrolled from EMRO countries. According to the results of the heterogeneity tests, we used fixed-effect/random-effect model for our meta-analysis, with the “Metan” command.ResultsWe included 30 studies, most of which were from Iran. The mean age of the subjects ranged from 13 to 27.1 years. The majority of the patients were male (range, 81% to 100%). The pooled estimate of HCV infection among patients with inherited coagulation disorders was 48.07% (95% confidence interval [CI], range: 27.39–55.68) in Iran, 36.03% (95% CI, range: 4.466–67.598) in Pakistan, and 48.27% (95% CI, range: 36.12–60.43) in all the EMRO countries taken together.ConclusionsIn Iran and other EMRO countries, the HCV infection rate among patients with inherited coagulation disorders is high. Our study shows that there is a lack of knowledge about infections in such patients in most of the EMRO countries. It is the responsibility of health-policy makers to address this knowledge gap and provide safe and adequate treatment for patients in high-risk groups.

show abstract

Inherited coagulation disorders in the northwestern region of Iran

Cited by 9 publications

References 6 publications

Lack of Knowledge About Hepatitis C Infection Rates Among Patients With Inherited Coagulation Disorders in Countries Under the Eastern Mediterranean Region Office of WHO (EMRO): A Meta-Analysis

Lack of Knowledge About Hepatitis C Infection Rates Among Patients With Inherited Coagulation Disorders in Countries Under the Eastern Mediterranean Region Office of WHO (EMRO): A Meta-Analysis

A study of reported factor VIII use around the world

Lack of Knowledge About Hepatitis C Infection Rates Among Patients With Inherited Coagulation Disorders in Countries Under the Eastern Mediterranean Region Office of WHO (EMRO): A Meta-Analysis

Contact Info

Product

Resources

About